Ethnopharmacological Relevance: Indigo naturalis is used by traditional Chinese medicine to treat various inflammatory diseases.
Aim Of The Study: Topical indigo naturalis ointment showed efficacy in treating psoriasis in our previous clinical studies. In this study, we investigated the anti-inflammatory effects of the extract of indigo naturalis (QD) and its main components indirubin, indigo, and tryptanthrin in human neutrophils.
Materials And Methods: Superoxide anion (O2(.-)) generation and elastase release were measured by spectrophotometry. Some important signals including mitogen-activated protein kinase (MAPK), cAMP, and calcium were studied by Western blot analysis, an enzyme immunoassay, and spectrofluorometry.
Results: QD significantly inhibited O2(.-) generation and elastase release in formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP)-activated human neutrophils in a concentration-dependent fashion, while neither indirubin, indigo, nor tryptanthrin produced a comparable result. QD attenuated the FMLP-induced phosphorylation of extracellular regulated kinase, p38 MAPK, and c-Jun N-terminal kinase. Furthermore, QD inhibited calcium mobilization caused by FMLP. However, QD did not affect cellular cAMP levels. On the other hand, neither indirubin, indigo, nor tryptanthrin produced similar changes in human neutrophils.
Conclusions: Taken collectively, these findings indicate that QD, but not indirubin, indigo, or tryptanthrin, inhibited O2(.-) generation and elastase release in FMLP-induced human neutrophils, which was at least partially mediated by the inhibition of MAPK activation and regulation of calcium mobilization.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jep.2009.06.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Induction treatments with and without addition of one dose anthracycline to all-trans retinoid acid and arsenic in pediatric non-high-risk acute promyelocytic leukemia: study protocol for a randomized controlled trial.
Trials
December 2024
Department of Pediatrics, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Article Synopsis
- Acute promyelocytic leukemia (APL) treatment has improved significantly with all-trans retinoic acid (ATRA) and arsenic, but issues like coagulation disorders and differentiation syndrome still pose risks, especially in children.
- A multicenter randomized trial compares the effectiveness of ATRA plus chemotherapy (experimental group) against ATRA alone (control group) in treating pediatric patients with APL, focusing on reducing hyperleukocytosis and complications.
- The goal is to determine whether adding chemotherapy during treatment induction is beneficial in lowering mortality rates among non-high-risk pediatric APL patients.
Malignant lymphoma is a relatively rare complication in patients with ulcerative colitis (UC) and its etiology is unclear. We present a hard-to-diagnose case of Epstein-Barr virus-positive diffuse large B-cell lymphoma in an elderly patient with UC who was treated with the immunomodulator tacrolimus and herbal medicine including indigo naturalis. Because malignant lymphomas can mimic other inflammatory diseases macroscopically, diagnosis in such cases can be challenging.
View Article and Find Full Text PDFArsenic trioxide versus Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trial.
Haematologica
November 2024
Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province.
Realgar-Indigo Naturalis Formula (RIF) is an oral form of arsenic that is effective against acute promyelocytic leukemia (APL). This multicenter, randomized, controlled trial compared the efficacy of all-trans retinoic acid (ATRA) plus RIF with ATRA plus arsenic trioxide (ATO) in a simplified regimen for non-high-risk APL. Following induction therapy with ATRA and ATO, participants were randomly assigned to receive either ATRA plus ATO or ATRA plus RIF both in a 2-week on 2-week off schedule for consolidation therapy.
View Article and Find Full Text PDFClinical, pharmacology and in vivo studies of QingDai (indigo naturalis) promotes mucosal healing and symptom improvement in ulcerative colitis by regulating the AHR-Th17/Treg pathway.
J Inflamm (Lond)
November 2024
Department of Traditional Chinese Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P.R. China.
Qingdai (QD), derived from various plant sources, is commonly used in traditional Chinese medicine for ulcerative colitis (UC) treatment. However, the clinical efficacy and mechanisms of orally administered QD remain unclear. This study aims to evaluate QD's efficacy in UC treatment and uncover its active components and mechanisms.
View Article and Find Full Text PDFas a potential drug in the treatment of ulcerative colitis: a comprehensive review of current evidence.
Pharm Biol
December 2024
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Article Synopsis
- Ulcerative colitis (UC) is a challenging inflammatory bowel disease with limited treatment options, prompting the need for safer and more effective drugs.
- Recent studies show that 'Indigo naturalis' (IN), a traditional Chinese medicine, has strong anti-inflammatory, antioxidant, and immunomodulatory effects, making it a promising candidate for UC treatment.
- Key components like indirubin and indigo from IN have been shown to effectively treat severe UC, but potential risks such as pulmonary hypertension highlight the need for careful use and further research on its therapeutic value.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!